Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions

Seminars in Liver Disease

Volumn 32, Issue 4, 2012, Pages 348-359

  Bolondi, Luigi ^a   Burroughs, Andrew ^b   Dufour, Jean François ^c   Galle, Peterr R ^d   Mazzaferro, Vincenzo ^e   Piscaglia, Fabio ^a   Raoul, Jean Luc ^f   Sangro, Bruno ^g  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f INSTITUT PAOLI CALMETTES   (France)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Barcelona Clinic Liver Cancer; hepatocellular carcinoma; radioembolization; sorafenib; transarterial chemoembolization

Indexed keywords

SORAFENIB;

CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CATHETERIZATION; CHEMOEMBOLIZATION; DRUG EFFICACY; DRUG SAFETY; INTERMEDIATE STAGE OF HCC; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; TRANSARTERIAL RADIOEMBOLIZATION; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84873392306     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0032-1329906     Document Type: Review

References (82)

1. National Cancer Institute SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct. Available at: http://seer.cancer.gov/statfacts/html/livibd.html. Accessed August 24, 2012.
2. Berrino F., De Angelis R., Sant M., et al. EUROCARE Working group Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol: 2007; 8 9 773 783 (Pubitemid 47321600)
3. Verdecchia A., Francisci S., Brenner H., et al. EUROCARE-4 Working Group Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol: 2007; 8 9 784 796 (Pubitemid 47321601)
4. Forner A., Llovet J. M., Bruix J. Hepatocellular carcinoma. Lancet: 2012; 379 9822 1245 1255
5. Marrero J. A., Fontana R. J., Barrat A., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology: 2005; 41 4 707 716 (Pubitemid 40462931)
6. Cillo U., Vitale A., Grigoletto F., et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol: 2006; 44 4 723 731
7. Guglielmi A., Ruzzenente A., Pachera S., et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol: 2008; 103 3 597 604 (Pubitemid 351405970)
8. Bruix J., Sherman M. American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: an update. Hepatology: 2011; 53 3 1020 1022
9. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol: 2012; 56 4 908 943
10. Schwartz M., Roayaie S., Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol: 2007; 4 7 424 432 (Pubitemid 47039693)
11. Llovet J. M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet: 2003; 362 9399 1907 1917 (Pubitemid 37518510)
12. Clark H. P., Carson W. F., Kavanagh P. V., Ho C. P., Shen P., Zagoria R. J. Staging and current treatment of hepatocellular carcinoma. Radiographics: 2005; 25 01 S3 S23 (Pubitemid 41686059)
13. Llovet J. M. Treatment of Hepatocellular Carcinoma. Curr Treat Options Gastroenterol: 2004; 7 6 431 441 (Pubitemid 39585737)
14. Llovet J. M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology: 2003; 37 2 429 442 (Pubitemid 36152543)
15. Piscaglia F., Bolondi L. The intermediate hepatocellular carcinoma stage: Should treatment be expanded? Dig Liver Dis: 2010; 42 03 S258 S263
16. D'Avola D., Iñarrairaegui M., Pardo F., et al. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann Surg Oncol: 2011; 18 7 1964 1971
17. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol: 2007; 30 1 6 25 (Pubitemid 44900485)
18. Tsochatzis E. A., Germani G., Burroughs A. K. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol: 2010; 37 2 89 93
19. Terzi E., Golfieri R., Piscaglia F., et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demando" J Hepatol: 2012;; Epub ahead of print
20. Takayasu K., Arii S., Kudo M., et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol: 2012; 56 4 886 892
21. Oliveri R. S., Wetterslev J., Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev: 2011; 3 CD004787
22. Lencioni R., Llovet J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis: 2010; 30 1 52 60
23. Gillmore R., Stuart S., Kirkwood A., et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol: 2011; 55 6 1309 1316
24. Cammà C., Schepis F., Orlando A., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology: 2002; 224 1 47 54 (Pubitemid 34680374)
25. Raoul J. L., Sangro B., Forner A., et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev: 2011; 37 3 212 220
26. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology: 2010; 52 2 762 773
27. Meyer T., Roughton M., Yu D., et al. A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC) [Abstract 4025]. J Clin Oncol: 2010; 28 (suppl): 15s
28. Llovet J. M., Real M. I., Montaña X., et al. Barcelona Liver Cancer Group Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet: 2002; 359 9319 1734 1739 (Pubitemid 34607087)
29. Golfieri R., Cappelli A., Cucchetti A., et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology: 2011; 53 5 1580 1589
30. Varela M., Real M. I., Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol: 2007; 46 3 474 481 (Pubitemid 46201723)
31. Lammer J., Malagari K., Vogl T., et al. PRECISION V Investigators Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol: 2010; 33 1 41 52
32. Malagari K., Pomoni M., Kelekis A., et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol: 2010; 33 3 541 551
33. Grieco A., Marcoccia S., Miele L., et al. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepatogastroenterology: 2003; 50 49 207 212 (Pubitemid 36182969)
34. Saccheri S., Lovaria A., Sangiovanni A., et al. Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol: 2002; 13 10 995 999 (Pubitemid 35231855)
35. Lu W., Li Y., He X., Chen Y. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology: 2003; 50 54 2079 2083 (Pubitemid 37467998)
36. Ikeda K., Kumada H., Saitoh S., Arase Y., Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer: 1991; 68 10 2150 2154
37. Herber S. C., Otto G., Schneider J., et al. Transarterial chemoembolization in patients not eligible for liver transplantation: single-center results. AJR Am J Roentgenol: 2008; 190 4 1035 1042 (Pubitemid 351571512)
38. Ernst O., Sergent G., Mizrahi D., Delemazure O., Paris J. C., L'Herminé C. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol: 1999; 172 1 59 64 (Pubitemid 29028431)
39. Forner A., Ayuso C., Varela M., et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer: 2009; 115 3 616 623
40. Llovet J. M., Ricci S., Mazzaferro V., et al. SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med: 2008; 359 4 378 390
41. Kulik L. M., Carr B. I., Mulcahy M. F., et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology: 2008; 47 1 71 81 (Pubitemid 351171043)
42. Hsu C. Y., Hsia C. Y., Huang Y. H., et al. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol: 2012; 19 3 842 849
43. Zhang Z. M., Guo J. X., Zhang Z. C., Jiang N., Zhang Z. Y., Pan L. J. Therapeutic options for intermediate-advanced hepatocellular carcinoma. World J Gastroenterol: 2011; 17 13 1685 1689
44. Silva M. F., Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol: 2011; 55 5 1137 1147
45. Mazzaferro V., Llovet J. M., Miceli R., et al. Metroticket Investigator Study Group Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol: 2009; 10 1 35 43
46. Clavien P. A., Lesurtel M., Bossuyt P. M., Gores G. J., Langer B., Perrier A. OLT for HCC Consensus Group Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol: 2012; 13 1 e11 e22
47. Jelic S., Sotiropoulos G. C. ESMO Guidelines Working Group Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: 2010; 21 05 v59 v64
48. Ravaioli M., Grazi G. L., Piscaglia F., et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant: 2008; 8 12 2547 2557
49. Vibert E., Azoulay D., Hoti E., et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant: 2010; 10 1 129 137
50. Yao F. Y., Kerlan R. K. Jr, Hirose R., et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology: 2008; 48 3 819 827
51. Llovet J. M., Ricci S., Mazzaferro V., et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). Paper presented at: American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, IL
52. Cheng A. L., Kang Y. K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol: 2009; 10 1 25 34
53. Bruix J., Raoul J. L., Sherman M., et al. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): Subanalysis of SHARP trial based on Barcelona Clinic Liver Cancer (BCLC) stage. J Hepatol: 2009; 50 01 S28 S29
54. Lencioni R., Venook A. P., Marrero J. A., et al. Second Interim Results of the GIDEON (Global Investigation of Therapeutic DEcisions in HCC and of Its Treatment With SorafeNib) Study - Barcelona-Clinic Liver Cancer (BCLC) Stage Subgroup Analysis. Abs 6500. Abstract presented at: The European Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden
55. Marrero J. A., Lencioni R., Kudo M., et al. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. J Clin Oncol: 2011; 29 4001
56. Iavarone M., Cabibbo G., Piscaglia F., et al. SOFIA (SOraFenib Italian Assessment) study group Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology: 2011; 54 6 2055 2063
57. Piscaglia F., Trimarchi C., Terzi E., et al. The rate of HCC patients in Child-Pugh B untreatable with effective strategies according to AASLD guidelines increases with the progression of specific Child-Pugh score. Hepatology: 2010; 52 1168A
58. Burrel M., Reig M., Forner A., et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol: 2012; 56 6 1330 1335
59. Salem R., Lewandowski R. J., Mulcahy M. F., et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology: 2010; 138 1 52 64
60. Hilgard P., Hamami M., Fouly A. E., et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology: 2010; 52 5 1741 1749
61. Sangro B., Carpanese L., Cianni R., et al. European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology: 2011; 54 3 868 878
62. Sangro B., Iñarrairaegui M., Bilbao J. I. Radioembolization for hepatocellular carcinoma. J Hepatol: 2012; 56 2 464 473
63. Andreana L., Isgrò G., Marelli L., et al. Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: trans-arterial radio-embolisation of HCC. Cancer Treat Rev: 2012; 38 6 641 649
64. Iñarrairaegui M., Pardo F., Bilbao J. I., et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol: 2012; 38 7 594 601
65. Lewandowski R. J., Kulik L. M., Riaz A., et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant: 2009; 9 8 1920 1928
66. Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol: 2012; 83 2 216 224
67. Li X., Feng G. S., Zheng C. S., Zhuo C. K., Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol: 2004; 10 19 2878 2882 (Pubitemid 39303010)
68. Carmeliet P., Jain R. K. Angiogenesis in cancer and other diseases. Nature: 2000; 407 6801 249 257
69. Dufour J. F., Hoppe H., Heim M. H., et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist: 2010; 15 11 1198 1204
70. Chung Y., Kim B., Chen C., et al. Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): Second interim safety and efficacy analysis. J Clin Oncol: 2010; 28 4026
71. Lencioni R., Llovet J. M., Han G., et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. [Abstract LBA154] J Clin Oncol: 2012; 30 (suppl)
72. Akamatsu M., Yoshida H., Obi S., et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int: 2004; 24 6 625 629
73. Bartolozzi C., Lencioni R., Caramella D., et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology: 1995; 197 3 812 818
74. Becker G., Soezgen T., Olschewski M., Laubenberger J., Blum H. E., Allgaier H. P. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol: 2005; 11 39 6104 6109 (Pubitemid 43085049)
75. Marelli L., Stigliano R., Triantos C., et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev: 2006; 32 8 594 606 (Pubitemid 44645026)
76. Cheung T. T., Ng K. K., Chok K. S., et al. Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes. World J Gastroenterol: 2010; 16 24 3056 3062
77. NCCN NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancer. V2.2012. Available at: www.nccn.org. Accessed August 24, 2012
78. Kudo M., Izumi N., Kokudo N., et al. HCC Expert Panel of Japan Society of Hepatology Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis: 2011; 29 3 339 364
79. Omata M., Lesmana L. A., Tateishi R., et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int: 2010; 4 2 439 474
80. Tournoux-Facon C., Paoletti X., Barbare J. C., et al. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol: 2011; 54 1 108 114
81. Llovet J. M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology: 1999; 29 1 62 67 (Pubitemid 29023987)
82. Bruix J., Sala M., Llovet J. M. Chemoembolization for hepatocellular carcinoma. Gastroenterology: 2004; 127 5 01 S179 S188 (Pubitemid 39423386)